Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), a much milder form of the disease where the age of onset can sometimes be as late as the third or fourth decade of life, are caused by mutations in the same X-linked gene, a 14 kilobase (kb) transcript which is spread over more than 2 megabases of the human X chromosome. The corresponding protein, dystrophin, has a relative molecular mass of 400,000. Most mutations causing DMD and BMD are deletions and deletions associated with both phenotypes are observed throughout the gene sequence. This observation led to the suggestion that DMD patients possess deletions that disrupt the reading frame of the protein, whereas BMD patients have deletions that retain the translational reading frame and enable the muscle cells to produce altered dystrophin products. This theory is supported by immunoblotting studies, which show that DMD patients lack dystrophin in their muscle cells or that dystrophin is present at very low levels, whereas BMD patients produce a protein with reduced abundance or abnormal size. Here we describe a deletion of the dystrophin gene in a family segregating for very mild BMD, one member of which was still ambulant at age 61 years, which removes a central part of the dystrophin gene encompassing 5,106 base pairs of coding sequence, almost half the coding information. Immunological analysis of muscle from one of the patients demonstrates that this mutation results in the production of a truncated polypeptide localized correctly in the muscle cell. These results are particularly significant in the context of gene therapy which, if it is ever envisaged, would be facilitated by the replacement of the very large dystrophin gene with a more manipulatable mini-gene construct.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, many shortened versions of the Duchenne muscular dystrophy gene (DMD; 2.3 Mb; 79-exons; 3685 amino acids; 11,055 bp) do not rescue the Duchenne muscular dystrophy phenotype in muscle cells except for the micro-dystrophin for which was reported a milder clinical phenotype [183,184].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [184]
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961
Hoffman, E. P., Fischbeck, K. H., Brown, R. H., Johnson, M., Medori, R., Loire, J. D., Harris, J. B., Waterston, R., Brooke, M., Specht, L., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805263182104 · Cited by 927
Self-citationThe Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle
Zubrzycka-Gaarn, E. E., Bulman, D. E., Karpati, G., Burghes, A. H. M., Belfall, B., Klamut, H. J., Talbot, J., Hodges, R. S., Ray, P. N., & Worton, R. G. (1988) · Nature · doi:10.1038/333466a0 · Cited by 658
Self-citationAn autosomal transcript in skeletal muscle with homology to dystrophin
Love, D. R., Hill, D. F., Dickson, G., Spurr, N. K., Byth, B. C., Marsden, R. F., Walsh, F. S., Edwards, Y. H., & Davies, K. E. (1989) · Nature · doi:10.1038/339055a0 · Cited by 494
Self-citationAnalysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy
co-authors, & Kunkel, L. M. (1986) · Nature · doi:10.1038/322073a0 · Cited by 474
Immunoelectron microscopic localization of dystrophin in myofibres
Watkins, S. C., Hoffman, E. P., Slayter, H. S., & Kunkel, L. M. (1988) · Nature · doi:10.1038/333863a0 · Cited by 449
Davies, K. E., Pearson, P. L., Harper, P. S., Murray, J. M., O'Brien, T., Sarfarazi, M., & Williamson, R. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.8.2303 · Cited by 397
Self-citation
Research works printed but not linked: 5
- Darras, B. T. & Francke, U. Am. J. hum. Genet. 43, 612–619 (1988).
- Love, D. R. & Davies, K. E. Molec biol. Med. 6, 7–17 (1989).
- Davies, K. E. et al. J. Med. Genet. 99, 99 (1987).
- Koenig, M., et al. Am. J. hum. Genet. 45, 498–506 (1989).
- Den Dunnen, J. T. Am. J. hum. Genet, in the press.
Cited by
Items 101–200 of 617
Ultrastructural localization of dystropin in human muscle by using gold immunolabelling
Cullen, M. J., Walsh, J., Nicholson, L. V. B., & Harris, J. B. (1990) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1990.0034 · Cited by 116
Self-citationYoshimura, M., Sakamoto, M., Ikemoto‐Uezumi, M., Mochizuki, Y., Yuasa, K., Miyagoe‐Suzuki, Y., & Takeda, S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.025 · Cited by 118
AAV-based gene therapies for the muscular dystrophies
Crudele, J. M., & Chamberlain, J. S. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz128 · Cited by 125
“8 kb (7), illustrating that much of the dystrophin protein can be omitted with minimal impact on function.”
BackgroundBogle, C., Colan, S. D., Miyamoto, S. D., Choudhry, S., Hernandez, N. B., Brickler, M. M., Feingold, B., Lal, A. K., Lee, T. M., Canter, C. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001151 · Cited by 123
Hakim, C. H., Wasala, N. B., Pan, X., Kodippili, K., Yue, Y., Zhang, K., Yao, G., Haffner, B., Duan, S. X., Ramos, J. N., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.06.006 · Cited by 118
“In the early 1990s, England et al.(8) found that some naturally occurring rod domain-truncated dystrophins are highly functional, suggesting that not all internal segments of dystrophin are essential.”
BackgroundTherapeutic approaches to muscular dystrophy
Goyenvalle, A., Seto, J. T., Davies, K. E., & Chamberlain, J. S. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr105 · Cited by 127
Self-citationLairmore, T. C., Howe, J. R., Korte, J. A., Dilley, W. G., Aine, L., Aine, E., Wells, S. A., & Donis-Keller, H. (1991) · Genomics · doi:10.1016/0888-7543(91)90237-9 · Cited by 110
Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy
Shieh, P. B. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-00687-z · Cited by 117
Fabb, S. A., Wells, D. J., Serpente, P., & Dickson, G. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.7.733 · Cited by 118
“A similar mild phenotype was also observed when exons 17–48 (5) and 17–51 (8) were deleted.”
BackgroundZaidman, C. M., Proud, C. M., McDonald, C. M., Lehman, K. J., Goedeker, N. L., Mason, S., Murphy, A. P., Guridi, M., Wang, S., Reid, C., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26755 · Cited by 102
Deletion analysis of the dystrophin‐actin binding domain
Corrado, K., Mills, P. L., & Chamberlain, J. S. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00397-1 · Cited by 101
Emerging drugs for Duchenne muscular dystrophy
Malik, V., Rodino‐Klapac, L. R., & Mendell, J. R. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.691965 · Cited by 113
“, diverse truncated dystrophin proteins) result in variable severity of disease related to the ability of the truncated dystrophin peptide to correct the underlying defect [5].”
BackgroundSkipping Multiple Exons to Treat DMD—Promises and Challenges
Aslesh, T., Maruyama, R., & Yokota, T. (2018) · Biomedicines · doi:10.3390/biomedicines6010001 · Cited by 104
“Variation in the severity of the disorder opened gateways to various therapeutics in order to ameliorate the severity to a milder phenotype, which is BMD [12].”
BackgroundInfluentialMicro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients
Duan, D. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.012 · Cited by 110
“It was found that BMD patients who lost nearly half of the gene still lived quite a healthy life, suggesting half-size dystrophin is protective in human patients.(5) Subsequent studies in animal models confirmed that the 6–8 kb mini-dystrophin genes indeed provided excellent protection.”
BackgroundBostick, B., Yue, Y., Long, C., Marschalk, N., Fine, D. M., Chen, J., & Duan, D. (2009) · Molecular Therapy · doi:10.1038/mt.2008.264 · Cited by 99
“0 BL10 (11) Strain (N ) Mdx (8) Tg (11) Li ne 2 7”
CRISPR-mediated genome editing and human diseases
Cai, L., Fisher, A. L., Huang, H., & Xie, Z. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.07.003 · Cited by 83
“Duchenne muscular dystrophy (DMD), a fatal genetic muscle disease, is produced by in-frame deletions affecting the dystrophin gene.(63) Research laboratories of Charles A.”
BackgroundGene Therapy of mdx Mice With Large Truncated Dystrophins Generated by Recombination Using rAAV6
Odom, G. L., Gregorevic, P., Allen, J. M., & Chamberlain, J. S. (2011) · Molecular Therapy · doi:10.1038/mt.2010.205 · Cited by 95
Viral-mediated gene therapy for the muscular dystrophies: Successes, limitations and recent advances
Odom, G. L., Gregorevic, P., & Chamberlain, J. S. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.09.007 · Cited by 114
“The cDNA used in this study was deleted for segments encoded on exons 17 to 48 producing a ~200 kd protein that lacks most of the central rod domain, and was previously observed in a BMD patient [74].”
BackgroundMethodInfluentialNicholson, L. V. B., Johnson, M. A., Bushby, K. M. D., Gardner‐Medwin, D., Curtis, A., Ginjaar, I. B., den Dunnen, J. T., Welch, J. L., Butler, T. J., & Bakker, E. (1993) · Journal of Medical Genetics · doi:10.1136/jmg.30.9.728 · Cited by 109
Self-citationZhang, Y., & Duan, D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.131 · Cited by 95
“Interestingly, the phenotype is much milder in some patients that carry large in-frame rod domain deletion (Gillard et al., 1989; Koenig et al., 1989; England et al., 1990; Beggs et al., 1991).”
BackgroundMalerba, A., Sharp, P. S., Graham, I. R., Arechavala‐Gomeza, V., Foster, K., Muntoni, F., Wells, D. J., & Dickson, G. (2010) · Molecular Therapy · doi:10.1038/mt.2010.261 · Cited by 100
Williams, M. W., & Bloch, R. J. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.144.6.1259 · Cited by 94
“However, changes that inhibit binding to the glycoprotein complex are associated with the severest forms of dystrophy (10, 24, 65, 84).”
BackgroundBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“3 Mb; 79-exons; 3685 amino acids; 11,055 bp) do not rescue the Duchenne muscular dystrophy phenotype in muscle cells except for the microdystrophin for which was reported a milder clinical phenotype [183,184].”
BackgroundShimizu-Motohashi, Y., Komaki, H., Motohashi, N., Takeda, S., Yokota, T., & Aoki, Y. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010001 · Cited by 82
“The identification of patients with a mild phenotype who carry large deletions [6,38] led to a suggestion that delivery of specific domains of dystrophin could be functional [39].”
BackgroundExon skipping and translation in patients with frameshift deletions in the dystrophin gene.
Sherratt, T. G., Vulliamy, T., Dubowitz, V., Sewry, C. A., & Strong, P. N. (1993) · Europe PMC (PubMed Central) · Cited by 103
Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin
Scott, J. M., Li, S., Harper, S. Q., Welikson, R. E., Bourque, D. L., DelloRusso, C., Hauschka, S. D., & Chamberlain, J. S. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00078-0 · Cited by 106
“Large deletions in the rod domain, sometimes removing up to half the dystrophin gene, have been identified in some BMD patients [14,15].”
BackgroundDetermination of the exon structure of the distal portion of the dystrophin gene by vectorette PCR
Roberts, R. G., Coffey, A. J., Bobrow, M., & Bentley, D. (1992) · Genomics · doi:10.1016/0888-7543(92)90005-d · Cited by 100
Ferlini, A., Neri, M., & Gualandi, F. (2012) · Neuromuscular Disorders · doi:10.1016/j.nmd.2012.09.002 · Cited by 91
“[54] England SB, Nicholson LV, Johnson MA, et al.”
BackgroundTsoumpra, M. K., Fukumoto, S., Matsumoto, T., Takeda, S., Wood, M. J. A., & Aoki, Y. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.036 · Cited by 98
“Therefore modification of dystrophin pre-mRNA processing that results to the production of an internally deleted proteinwhile preserving the N- and C- terminaldomainswhichlinkto thecytoskeletonandextracellularmatrix respectivelymight be the key to DMD future gene therapy [49].”
BackgroundArahata, K., Beggs, A. H., Honda, H., Ito, S., Ishiura, S., Tsukahara, T., Ishiguro, T., Eguchi, C., Orimo, S., Arikawa, E., et al. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90039-a · Cited by 101
Arechavala-Gomeza, V., Anthony, K., Morgan, J., & Muntoni, F. (2012) · Current Gene Therapy · doi:10.2174/156652312800840621 · Cited by 94
“Antisense oligonucleotides (AOs) targeted to splicing elements within DMD pre-mRNA can induce the skipping of targeted exons, restoring the ORF and the consequent production of a shorter but functional dystrophin protein.”
BackgroundInfluentialClinical development on the frontier: gene therapy for duchenne muscular dystrophy
Asher, D. R., Thapa, K., Dharia, S. D., Khan, N., Potter, R. A., Rodino‐Klapac, L. R., & Mendell, J. R. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1725469 · Cited by 99
Becker muscular dystrophy severity is linked to the structure of dystrophin
Nicolas, A., Raguénès‐Nicol, C., Yaou, R. B., Hir, S. A.-L., Cheron, A., Vié, V., Claustres, M., Leturcq, F., Delalande, O., Hubert, J., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu537 · Cited by 103
“This deletion was originally observed in a patient (37) and contains “non-phased” repeats that give rise to a fractional repeat according to our predictions.”
Blankinship, M. J., Gregorevic, P., & Chamberlain, J. S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.001 · Cited by 96
Price, A., Rayner, L., Okon-Rocha, E., Evans, A., Valsraj, K., Higginson, I. J., & Hotopf, M. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.230862 · Cited by 90
Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy
Ferrer, A., Wells, K. E., & Wells, D. J. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301259 · Cited by 89
REVIEW: The membrane--cytoskeleton interface: the role of dystrophin and utrophin
Winder, S. J. (1997) · Journal of Muscle Research and Cell Motility · doi:10.1023/a:1018627705273 · Cited by 102
Shimizu‐Motohashi, Y., Miyatake, S., Komaki, H., Takeda, S., & Aoki, Y. (2016) · Europe PMC (PubMed Central) · Cited by 101
Transfection of large plasmids in primary human myoblasts
Campeau, P. M., Chapdelaine, P., Seigneurin-Venin, S., Massie, B., & Tremblay, J. P. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301532 · Cited by 87
Hoffman, E. P., García, C., Chamberlain, J. S., Angelini, C. I., Lupski, J. R., & Fenwick, R. G. (1991) · Annals of Neurology · doi:10.1002/ana.410300414 · Cited by 96
Goto, M., Sawamura, D., Nishie, W., Sakai, K., McMillan, J. R., Akiyama, M., & Shimizu, H. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700435 · Cited by 85
“In muscular dystrophy caused by mutations in the dystrophin gene, shorter transcripts found in patients with milder phenotypes have a significantly longer life expectancy when compared to the patients with a complete loss of dystrophin expression (Monaco et al., 1988; England et al., 1990).”
BackgroundAAV-microdystrophin Therapy Improves Cardiac Performance in Aged Female mdx Mice
Bostick, B., Shin, J.-H., Yue, Y., & Duan, D. (2011) · Molecular Therapy · doi:10.1038/mt.2011.154 · Cited by 85
The Influence of Antisense Oligonucleotide Length on Dystrophin Exon Skipping
Harding, P. L., Fall, A., Honeyman, K., Fletcher, S., & Wilton, S. D. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300006 · Cited by 82
Split intein-mediated protein trans-splicing to express large dystrophins
Tasfaout, H., Halbert, C. L., McMillen, T. S., Allen, J. M., Reyes, T. R., Flint, G. V., Grimm, D., Hauschka, S. D., Regnier, M., & Chamberlain, J. S. (2024) · Nature · doi:10.1038/s41586-024-07710-8 · Cited by 92
“England et al. reported that a patient carrying a deletion of 46% (exons 17–48) of the DMD gene was largely asymptomatic and remained ambulatory until the seventh decade while expressing a highly functional mini-dystrophin 43 .”
Functional Rescue of Dystrophin-deficient mdx Mice by a Chimeric Peptide-PMO
Yin, H., Moulton, H. M., Betts, C., Merritt, T. M., Seow, Y., Ashraf, S., Wang, Q., Boutilier, J. K., & Wood, M. J. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.151 · Cited by 81
Gene and cell‐mediated therapies for muscular dystrophy
Konieczny, P., Swiderski, K., & Chamberlain, J. S. (2012) · Muscle & Nerve · doi:10.1002/mus.23738 · Cited by 95
“The idea that functional miniature dystrophin constructs may be useful came from the finding that BMD patients with very mild dystrophy can carry large deletions in the dmd gene.(30) The generation of transgenic mdx mice engineered to carry dystrophin constructs lacking varying”
BackgroundWu, B., Lu, P., Cloer, C., Shaban, M., Grewal, S., Milazi, S., Shah, S. N., Moulton, H. M., & Lu, Q. L. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.04.006 · Cited by 82
Novel therapies for Duchenne muscular dystrophy
Kapsa, R. M. I., Kornberg, A. J., & Byrne, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00382-x · Cited by 91
Kodippili, K., Hakim, C. H., Pan, X., Yang, H. T., Yue, Y., Zhang, Y., Shin, J., Yang, N. N., & Duan, D. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.095 · Cited by 90
Yuasa, K., Miyagoe, Y., Yamamoto, K., Nabeshima, Y., Dickson, G., & Takeda, S. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00251-8 · Cited by 87
Aartsma-Rus, A. M., Kaman, W. E., Weij, R., den Dunnen, J. T., van Ommen, G. B., & van Deutekom, J. C. T. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.022 · Cited by 91
Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure
Rafael, J. A., Townsend, E. R., Squire, S. E., Potter, A. C., Chamberlain, J. S., & Davies, K. E. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.9.1357 · Cited by 99
Advances in genetic therapeutic strategies for Duchenne muscular dystrophy
Guiraud, S., Chen, H., Burns, D. T., & Davies, K. E. (2015) · Experimental Physiology · doi:10.1113/ep085308 · Cited by 81
“Based on a Becker patient with a very mild phenotype with 46% of dystrophin deleted (England et al. 1990), micro- and mini-dystrophin have been delivered using AAV vectors (Harper et al. 2002) (Fig.”
MethodSelf-citationToward the correction of muscular dystrophy by gene editing
Olson, E. N. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004840117 · Cited by 87
Meganucleases can restore the reading frame of a mutated dystrophin
Chapdelaine, P., Pichavant, C., Rousseau, J., Pâques, F., & Tremblay, J. P. (2010) · Gene Therapy · doi:10.1038/gt.2010.26 · Cited by 95
Zebrafish models flex their muscles to shed light on muscular dystrophies
Berger, J., & Currie, P. D. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.010082 · Cited by 98
Full-Length Dystrophin Reconstitution with Adeno-Associated Viral Vectors
Lostal, W., Kodippili, K., Yue, Y., & Duan, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.210 · Cited by 77
“For example, deletion of a large section of the dystrophin rod domain or the dystrophin C-terminal domain is tolerated in human patients and mice (England et al ., 1990; Crawford et al ., 2000; Harper et al ., 2002).”
Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes?
Tornabene, P., & Trapani, I. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.220 · Cited by 76
“However, the initial discovery of a highly functional mini-version of the dystrophin protein in mildly affected Becker muscular dystrophy patients, 26 as well as the numerous studies that have generated considerable knowledge regarding the structural domains of dystrophin, prompted rational design…”
Duchenne Muscular Dystrophy Gene Therapy in the Canine Model
Duan, D. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.006 · Cited by 88
“This minigene is isolated from a very mild patient who was ambulant at age 61.(57) A large portion of the rod domain (from exon 17 to 48) is absent in this minidystrophin because of an in-frame deletion.”
Vandebrouck, A., Ducret, T., Basset, O., Sebille, S., Raymond, G., Rüegg, U. T., Gailly, P. L., Cognard, C., & Constantin, B. (2005) · The FASEB Journal · doi:10.1096/fj.04-3633fje · Cited by 85
“3 kb minidystrophin cDNA has been cloned from an asymptomatic BMD patient (9).”
BackgroundTruncated dystrophins can influence neuromuscular synapse structure
Banks, G. B., Chamberlain, J. S., & Froehner, S. C. (2009) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.12.011 · Cited by 80
“Structure-function analyses of dystrophins expressed in the more mild form of DMD called Becker muscular dystrophy demonstrate that large in-frame deletions in the central rod domain can minimally affect the functional capacity of dystrophin (England et al., 1990).”
BackgroundSharp, P. S., Bye‐A‐Jee, H., & Wells, D. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.213 · Cited by 80
Emerging strategies for cell and gene therapy of the muscular dystrophies
Muir, L. A., & Chamberlain, J. S. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001100 · Cited by 76
Sequences of junction fragments in the deletion-prone region of the dystrophin gene
Love, D. R., England, S., Speer, A., Marsden, R. F., Bloomfield, J. F., Roche, A., Cross, G. S., Mountford, R., Smith, T., & Davies, K. E. (1991) · Genomics · doi:10.1016/0888-7543(91)90484-v · Cited by 77
Self-citationJablonka, S., Hennlein, L., & Sendtner, M. (2022) · Neurological Research and Practice · doi:10.1186/s42466-021-00162-9 · Cited by 86
Yue, Y., Liu, M., & Duan, D. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.007 · Cited by 74
“Some BMD patients are ambulant beyond age 60 [2].”
BackgroundEmerging genetic therapies to treat Duchenne muscular dystrophy
Nelson, S. F., Crosbie, R. H., Miceli, M. C., & Spencer, M. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32832fd487 · Cited by 72
“Unauth Notable reports of exceptionally mild (or asymptomatic) BMD in patients with large exon 45–55 deletions have led some investigators to explore the feasibility of developing a cocktail of AONs, which could be used as a single drug to treat as many as 63% of all patients with DMD [16,40].”
BackgroundInfluentialLentiviral vectors can be used for full-length dystrophin gene therapy
Counsell, J. R., Asgarian, Z., Meng, J., Ferrer, V., Vink, C. A., Howe, S. J., Waddington, S. N., Thrasher, A. J., Muntoni, F., Morgan, J. E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-00152-5 · Cited by 83
An intact cysteine-rich domain is required for dystrophin function.
Bies, R. D., Caskey, C. T., & Fenwick, R. G. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115909 · Cited by 72
“One dramatic example is the deletion of 46% of the dystrophin molecule in the central alpha-helical rod domain, which results in only very mild muscular dystrophy (7).”
BackgroundRetroviral‐mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro
Dunckley, M. G., Love, D. R., Davies, K. E., Walsh, F. S., Morris, G. E., & Dickson, G. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80363-l · Cited by 72
Self-citationU7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping
Brun, C., Suter, D., Pauli, C., Dunant, P., Lochm�ller, H., Burgunder, J., Schümperli, D., & Weis, J. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s000180300047 · Cited by 79
Zhang, Y., Yue, Y., Li, L., Hakim, C. H., Zhang, K., Thomas, G. D., & Duan, D. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt224 · Cited by 71
Duchenne Muscular Dystrophy: Current Knowledge, Treatment, and Future Prospects
Biggar, W. D., Klamut, H. J., Demacio, P. C., Stevens, D. J., & Ray, P. N. (2002) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-200208000-00012 · Cited by 84
Densmore, C. L., Giddings, T. H., Waldrep, J. C., Kinsey, B. M., & Knight, V. (1999) · The Journal of Gene Medicine · doi:10.1002/(sici)1521-2254(199907/08)1:4<245::aid-jgm49>3.0.co;2-g · Cited by 63
A truncated dystrophin lacking the C-terminal domains is localized at the muscle membrane.
Helliwell, T. R., Ellis, J. M., Mountford, R., Appleton, R. E., & Morris, G. E. (1992) · Europe PMC (PubMed Central) · Cited by 71
Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
Fortunato, F., Rossi, R., Falzarano, M. S., & Ferlini, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040820 · Cited by 64
“Genetic diagnosis is mandatory in DMD and BMD patients for many reasons: (1) genetic counseling and family planning, including female carrier identification and pre-implantation or prenatal diagnosis; (2) genotype-phenotype correlation and frame rule implications, which may predict mild or severe phenotypes and theref…”
BackgroundInfluentialLi, D., Yue, Y., & Duan, D. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.071042 · Cited by 74
“Some of these abbreviated dystrophin isoforms can be quite effective in halting disease progression.(4,5) In fact, several gene therapy strategies are based on expressing internally deleted dystrophin.”
BackgroundPalladino, M., Gatto, I., Neri, V., Straino, S., Smith, R. C., Silver, M., Gaetani, E., Marcantoni, M., Giarretta, I., Stigliano, E., et al. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.301172 · Cited by 75
“2867 In Duchenne muscular dystrophy (DMD), the protein dystrophin, which serves as a link between cytoskeletal actin and the extracellular matrix, is missing or defective.(1,2) Dystrophin expression is not limited to muscle tissues but is present in many other cell types, including endothelial cells (ECs).”
BackgroundYang, L., Lochmüller, H., Luo, J., Massie, B., Nalbantoglu, J. N., Karpati, G., & Petrof, B. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300600 · Cited by 83
Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy
Robinson-Hamm, J. N., & Gersbach, C. A. (2016) · Human Genetics · doi:10.1007/s00439-016-1725-z · Cited by 82
“Some inherited dystrophin mutations maintain the reading frame and result in production of an internally truncated, but partially functional, dystrophin protein (Hoffman et al. 1989; England et al. 1990; Helderman-van den Enden et al. 2010).”
BackgroundClinical Characteristics of Aged Becker Muscular Dystrophy Patients with Onset after 30 Years
Yazaki, M., Yoshida, K., Nakamura, A., Koyama, J., Nanba, T., Ohori, N., & Ikeda, S.-I. (1999) · European Neurology · doi:10.1159/000008089 · Cited by 76
“In contrast with DMD, BMD patients show much more heterogeneous clinical manifestations. In the clinical category, the limb disability in most patients with BMD starts in childhood or early adolescence, they remain ambulatory into their 20s, and the mean age at death is around the mid-40s [ , , , ,”
BackgroundWu, B., Xiao, B., Cloer, C., Shaban, M., Sali, A., Lu, P., Li, J., Nagaraju, K., Xiao, X., & Lu, Q. L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.288 · Cited by 68
Ohtsuka, Y., Udaka, K., Yamashiro, Y., Yagita∥, H., & Okumura, K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4635 · Cited by 76
Optimizing exon skipping therapies for DMD.
Yokota, T., Duddy, W. J., & Partridge, T. A. (2007) · Europe PMC (PubMed Central) · Cited by 67
Dystrophin and dystrophin-related proteins: A review of protein and RNA studies
Love, D. R., Byth, B. C., Tinsley, J. M., Blake, D. J., & Davies, K. E. (1993) · Neuromuscular Disorders · doi:10.1016/0960-8966(93)90037-k · Cited by 78
Self-citationManini, A., Abati, E., Nuredini, A., Corti, S. P., & Comi, G. P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.814174 · Cited by 82
“The result is a milder dystrophic phenotype compared to untreated subjects (83).”
BackgroundUtrophin Lacks the Rod Domain Actin Binding Activity of Dystrophin
Amann, K. J., Guo, A., & Ervasti, J. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.35375 · Cited by 82
Dystrophin mutations predict cellular susceptibility to oxidative stress
Disatnik, M.-H., Chamberlain, J. S., & Rando, T. A. (2000) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(200005)23:5<784::aid-mus17>3.0.co;2-y · Cited by 67
Calcium Misregulation and the Pathogenesis of Muscular Dystrophy
Hopf, F. W., Turner, P. R., & Steinhardt, R. A. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6191-2_16 · Cited by 75
Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice
Ito, K., Kimura, S., Ozasa, S., Matsukura, M., Ikezawa, M., Yoshioka, K., Ueno, H., Suzuki, M., Araki, K., Yamamura, K., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl151 · Cited by 72
“A milder form of DMD known as Becker muscular dystrophy (BMD) also is caused by mutations in the dystrophin gene, resulting in low level expression of a truncated protein (3, 4).”
BackgroundBiomarker Potential of Extracellular miRNAs in Duchenne Muscular Dystrophy
Coenen-Stass, A. M. L., Wood, M. J. A., & Roberts, T. C. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.09.002 · Cited by 68
Nicholson, L. V. B., Johnson, M. A., Bushby, K., Gardner‐Medwin, D., Curtis, A., Ginjaar, I. B., den Dunnen, J. T., Welch, J. L., Butler, T. J., & Bakker, E. (1993) · Journal of Medical Genetics · doi:10.1136/jmg.30.9.737 · Cited by 64
Self-citationDystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies
Rumeur, É. L. (2015) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2015.636 · Cited by 91
“Truncated gene coding sequences (micro-dys-trophins) inspired from the truncated dystrophin coding sequences observed in mild BMD patients [53](Figure 3) were designed [54-57].”
BackgroundFranz, W., Muller, M., Müller, O. J., Herrmann, R., Rothmann, T., Cremer, M., Cohn, R. D., Voït, T., & Katus, H. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02266-2 · Cited by 70
Progress in therapy for Duchenne muscular dystrophy
Fairclough, R. J., Bareja, A., & Davies, K. E. (2011) · Experimental Physiology · doi:10.1113/expphysiol.2010.053025 · Cited by 74
“Significantly, these deletions occur in the rod domain of the protein, encoding spectrin repeats (England et al. 1990; Love et al. 1991; Matsumura et al. 1994).”
BackgroundSelf-citationUpdate on the Treatment of Duchenne Muscular Dystrophy
Rodino‐Klapac, L. R., Mendell, J. R., & Sahenk, Z. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0332-1 · Cited by 69
“This phenomenon was initially based on a clinical observation in a Becker muscular dystrophy patient with a large in-frame deletion of exons 17–48 removing a significant portion of the rod domain [4].”
Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain
Banks, G. B., Gregorevic, P., Allen, J. M., Finn, E. E., & Chamberlain, J. S. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm158 · Cited by 66
Gene Therapy in Large Animal Models of Muscular Dystrophy
Wang, Z., Chamberlain, J. S., Tapscott, S. J., & Storb, R. F. (2009) · ILAR Journal · doi:10.1093/ilar.50.2.187 · Cited by 68
“…that some BMD patients with large deletions in the central rod domain display milder phenotypes than DMD patients suggested that this domain is of limited function and largely dispensable (Aartsma-Rus et al. 2006; Aartsma-Rus and van Ommen 2007; Abmayr and Chamberlain 2006; England et al. 1990).”
BackgroundSkipping toward Personalized Molecular Medicine
Hoffman, E. P. (2007) · New England Journal of Medicine · doi:10.1056/nejme0707795 · Cited by 60
Coenen-Stass, A. M. L., McClorey, G., Manzano, R., Betts, C., Blain, A. M., Saleh, A. F. A., Gait, M. J., Lochmüller, H., Wood, M. J. A., & Roberts, T. C. (2015) · Scientific Reports · doi:10.1038/srep17014 · Cited by 61
Metadata
- Authors
- England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E.
- Affiliations
- John Radcliffe Hospital (GB)
- Hospital for Sick Children (CA)
- Venue
- Nature
- Published
- 1990-01
- Volume
- 343
- Issue
- 6254
- Pages
- 180-182
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2058807250
- Cited by
- 623
- References
- 25
- Citations by year
- 2026: 18 · 2025: 21 · 2024: 20 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 16 · 2018: 20 · 2017: 18 · 2016: 20 · 2015: 23 · 2014: 16 · 2013: 17 · 2012: 22
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- Becker muscular dystrophy, Duchenne muscular dystrophy, dystrophin gene deletion, dystrophin, X-linked inheritance, reading frame, gene therapy
- MeSH terms
- Chromosome Deletion, Exons, Female, Genes, Humans, Male, Middle Aged, Muscle Proteins, Muscles, Muscular Dystrophies, Nucleic Acid Hybridization, Pedigree, Protein Conformation, Reference Values, Blotting, Western, Restriction Mapping, Dystrophin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.